Eli Lilly New Zealand
the first registered dual GLP1 and GIP receptor agonist – is now available in New Zealand.
Mounjaro is a once weekly injectable medicine that acts on both GLP1 and GIP receptors to improve blood sugar control and provide clinically meaningful weight reduction in appropriate patients.
The medicine was evaluated under the Medsafe priority review pathway, which is a fast-track pathway for medicines of clinical significance that could be useful to help meet current Public Health challenges.
Mounjaro was the highest selling prescription medicine brand in Australia in 2025.
Refer to the full press release f
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).
